Who
Mark A. Glickman
Director
Company insider
Files Form 4 as: Director, BioStem Technologies; Director, MetaVia; Co-Chief Executive Officer, TherapeuticsMD; Chief Commercial Officer, Esperion Therapeutics; Chief Commercial Officer, Aralez Pharmaceuticals; Chief Commercial Officer, Pozen Inc /nc; EVP - Sales and Marketing, Auxilium Pharmaceuticals; SVP, Sales & Marketing, Oscient Pharmaceuticals.
In numbers
- Trades disclosed
- 62
- Buys
- 1
- Sells
- 3
- Bought
- $92K
- Sold
- $1.6M
- Companies
- 8
- Companies where not an officer
- 2
- First trade
- 28 Jul 2008
- Last trade
- 27 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 28 Aug 2026 | BSEM BioStem TechnologiesBiotechnology | SEC FORM 4 Code M | —7,671 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | BSEM BioStem Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,671 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | BSEM BioStem Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,671 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | BSEM BioStem TechnologiesBiotechnology | SEC FORM 4 Code M | —7,671 at $0.00 | filing |
| 8 Jun 2026filed 8 Jun 2026 | MTVA MetaViaBiotechnology | SEC FORM 4 Code A | —17,186 at $0.00 | filing |
| 8 Jun 2026filed 8 Jun 2026 | MTVA MetaViaBiotechnology | SEC FORM 4 Code A | —17,186 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | MTVA MetaViaBiotechnology | SEC FORM 4 Code A | —28,147 at $0.00 | filing |
| 7 Jun 2024filed 7 Jun 2024 | MTVA MetaViaBiotechnology | SEC FORM 4 Code A | —5,051 at $0.00 | filing |
| 27 Jul 2023filed 28 Jul 2023 | MTVA MetaViaBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2023filed 28 Jul 2023 | MTVA MetaViaBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 6 Dec 2022filed 9 Dec 2022 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,734 at $0.00 | filing |
| 6 Dec 2022filed 9 Dec 2022 | TXMD TherapeuticsMDBiotechnology | SEC FORM 4 Code M | —1,734 at $0.00 | filing |
| 6 Dec 2022filed 9 Dec 2022 | TXMD TherapeuticsMDBiotechnology | SEC FORM 4 Sold | $2,165440 at $4.92 | filing |
| 31 Mar 2022filed 31 Mar 2022 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
| 23 Mar 2022filed 28 Mar 2022 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
| 15 Oct 2021filed 15 Oct 2021 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
| 15 Oct 2021filed 15 Oct 2021 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
| 15 Oct 2021filed 15 Oct 2021 | TXMD TherapeuticsMDoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 2 Jan 2020filed 3 Jan 2020 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,625 at $0.00 | filing |
| 2 Jan 2020filed 3 Jan 2020 | Esperion Therapeutics | SEC FORM 4 Code A | —5,925 at $0.00 | filing |
News
TherapeuticsMD (NASDAQ:TXMD) vs. Addex Therapeutics (NASDAQ:ADXN) Head to Head ComparisonTXMD · tickerreport.com · 14 Oct 2026GSK (NYSE:GSK) & TherapeuticsMD (NASDAQ:TXMD) Head to Head ComparisonTXMD · tickerreport.com · 6 Oct 2026
0 headlines in the last 90 days name Mark A. Glickman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.